Myelodysplastic syndrome

Fusion driven JMML: a novel CCDC88C–FLT3 fusion responsive to sorafenib identified by RNA sequencing

Article metrics

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1
Fig. 2


  1. 1.

    Stieglitz E, Ward AF, Gerbing RB, Alonzo TA, Arceci RJ, Liu YL, et al. Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children’s Oncology Group. Pediatr blood cancer. 2015;62:629–36.

  2. 2.

    Dvorak CC, Satwani P, Stieglitz E, Cairo MS, Dang H, Pei Q, et al. Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: sa Children’s Oncology Group study. Pediatr blood cancer. 2018;65:e27034.

  3. 3.

    Stieglitz E, Taylor-Weiner AN, Chang TY, Gelston LC, Wang YD, Mazor T, et al. The genomic landscape of juvenile myelomonocytic leukemia. Nat Genet. 2015;47:1326–33.

  4. 4.

    Stieglitz E, Troup CB, Gelston LC, Haliburton J, Chow ED, Yu KB, et al. Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia. Blood. 2015;125:516–24.

  5. 5.

    Locatelli F, Nollke P, Zecca M, Korthof E, Lanino E, Peters C, et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood. 2005;105:410–9.

  6. 6.

    Murakami N, Okuno Y, Yoshida K, Shiraishi Y, Nagae G, Suzuki K, et al. Integrated molecular profiling of juvenile myelomonocytic leukemia. Blood. 2018;131:1576–86.

  7. 7.

    Baldwin BR, Li L, Tse KF, Small S, Collector M, Whartenby KA, et al. Transgenic mice expressing Tel-FLT3, a constitutively activated form of FLT3, develop myeloproliferative disease. Leukemia. 2007;21:764–71.

  8. 8.

    Falchi L, Mehrotra M, Newberry KJ, Lyle LM, Lu G, Patel KP, et al. ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant. Leukemia. 2014;28:2090–2.

  9. 9.

    Stirewalt DL, Kopecky KJ, Meshinchi S, Engel JH, Pogosova-Agadjanyan EL, Linsley J, et al. Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. Blood. 2006;107:3724–6.

  10. 10.

    Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98:1752–9.

  11. 11.

    Bown N, Y SM, Evans J, Kernahan J, Reid MM. Chronic myelomonocytic leukemia with t(13;14) in a child. Cancer Genet Cytogenet. 1992;60:190–2. 1992

  12. 12.

    Buijs A, Bruin M. Fusion of FIP1L1 and RARA as a result of a novel t(4;17)(q12; q21) in a case of juvenile myelomonocytic leukemia. Leukemia. 2007;21:1104–8.

  13. 13.

    Morerio CA M, Rosanda C, Rapella A, Dufour C, Locatelli F, Maserati E, et al. HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile myelomonocytic leukemia with t(5;17)(q33; p11.2). Cancer Res. 2014;64:2649–51.

  14. 14.

    Byrgazov K, Kastner R, Dworzak M, Hoermann G, Haas OA, Ulreich R, et al. A novel fusion gene NDEL1-Pdgfrb in a patient with JMML with a new variant of TKI-resistant mutation in the kinase domain of PDGFR beta. Blood. 2014;124:613.

  15. 15.

    Mizoguchi Y, Fujita N, Taki T, Hayashi Y, Hamamoto K. Juvenile myelomonocytic leukemia with t(7;11)(p15; p15) and NUP98-HOXA11 fusion. Am J Hematol. 2009;84:295–7.

Download references


We thank the family for their willingness to share their story. This work was supported by the National Institutes of Health, National Cancer Institute grant 1U54CA196519 (M.L.L., E.S.); National Institutes of Health, National Heart, Lung, and Blood Institute grant K08HL135434 (E.S.); Alex’s Lemonade Stand, Center of Excellence (M.L.L., E.S.) and the Frank A. Campini Foundation (M.L.L. and E.S.). C.S. is the Damon Runyon-Richard Lumsden Foundation Clinical Investigator supported (in part) by the Damon Runyon Cancer Research Foundation (CI-99-18).

Author information

A.K.C. and J.A.M. performed the ddPCR and Ba/F3 experiments and analyzed the data; A.G.L. and J.V.Z. analyzed the data; A.K.K., B.S.B., E.A.S., C.C.S., C.C.D., T.T., A.H. all advised on design of the experiments; A.K.C. and E.S. wrote the manuscript; J.A.M., A.G.L., J.V.Z., A.K.K., C.G., B.S.B, E.A.S., C.C.S., C.C.D., M.L.L., T.T., A.H. edited the manuscript; E.S. supervised the experiments; and all authors reviewed the literature, contributed to specific sections, and reviewed the final version of the manuscript.

Correspondence to Elliot Stieglitz.

Ethics declarations

Conflict of interest

C.S. received research funding from FujiFilm and Astellas Pharma. A.K.C. received an honoraria from Bio-Rad for speaking at a symposium. No other authors declare conflicts of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Further reading